Skip to main content

11 results for "DREADD Activators" in Products

DREADD Activators Products

DREADD Mechanism of Action

The first DREADDs to be developed were derived from human muscarinic acetylcholine receptors (mAChRs) and termed hM1-5. These receptors have mutations in their orthosteric binding site, abolishing their affinity for the endogenous ligand ACh, while rendering them responsive to small molecule DREADD ligands, such as Clozapine-N-oxide (CNO, Cat. No. 4936) or Deschloroclozapine (DCZ, Cat. No. 7193).

The effect of ligand binding depends on the G protein-coupling of the ...

Show More

Potent hM3Dq and hM4Di DREADD agonist; water soluble version of DREADD agonist 21 (Cat. No. 5548)

Activator of hM3Dq and hM4Di DREADDs; water soluble version of Clozapine N-oxide (Cat. No. 4936)

Potent hM3Dq and hM4Di DREADD agonist; blood brain barrier penetrant

Activator of hM3Dq and hM4Di DREADDs

High affinity and highly potent activator of hM3Dq and hM4Di DREADDs; rapid blood-brain barrier penetrant

Activator of κ-opioid DREADD (KORD)

High affinity and highly potent hM3Dq and hM4Di DREADD agonist; blood brain barrier penetrant

High affinity and highly potent hM3Dq and hM4Di DREADD agonist; blood brain barrier penetrant

Potent hM3Dq and hM4Di DREADD agonist in vitro

Selective orthostatic agonist of hFFA2-DREADDs

5-HT2A antagonist; also D2 antagonist; atypical antipsychotic

Results Per Page
5 10 25 50
/ 1